Adults 3 Days to 14 Days, any sex, with Bronchopulmonary Dysplasia. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Subjects With Treatment-emergent Adverse Events During the Post-treatment Phase (Safety and Tolerability)Primary· From Day 1 to 40 Weeks Post-menstrual Age or Hospital Discharge, whichever came first
The safety and tolerability of UNEX-42 in subjects with BPD was evaluated by the number of subjects with treatment-emergent adverse events, including death, computed by dose cohort and overall during the Post-treatment Phase.
Group
Value
95% CI
20 Pmol Phospholipid/kg Body Weight
2
60 Pmol Phospholipid/kg Body Weight
0
200 Pmol Phospholipid/kg Body Weight
0
Placebo
1
Adverse events — posted to ClinicalTrials.gov
Time frame: From Day -2 to 40 Weeks Post-menstrual Age or Hospital Discharge, whichever came first.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
A multicenter, placebo-controlled, randomized, dose escalation, safety, and tolerability study of UNEX-42 in infants born at \<27 weeks of gestational age (GA) at high risk for bronchopulmonary dysplasia (BPD).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
Other recruiting trials for Bronchopulmonary Dysplasia
Currently open trials in the same condition.
NCT06589245 — Inhaled Ciclesonide Study in Preterm Infants
· Phase 1
· recruiting
NCT06512935 — Ventilator Pressure and Optimization of Compliance and Hemodynamics
· NA
· recruiting
NCT06534359 — Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia
· NA
· recruiting
NCT06808997 — Prospective Multicentre Mixed Methods Study to Explore Extubation Practices and Respiratory Outcomes in Extremely Preter
· recruiting
NCT06897839 — Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)
· Phase 2, PHASE3
· recruiting
Other United Therapeutics trials
Trials by the same sponsor.
NCT06388421 — DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease
· recruiting
NCT05060315 — Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin
· terminated
NCT05203510 — A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right
· Phase 4
· active not recruiting
NCT05255991 — Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
· Phase 3
· completed
NCT04708782 — Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
· Phase 3
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by United Therapeutics
Last refreshed: 12 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03857841.